New York, April 2022: According to a new research study by Global Insight Services (GIS), the aspiration & biopsy needles market is expected to grow rapidly over the next 10 years to reach a value of more than the US $889 million by 2031.

A needle biopsy is a procedure to obtain a sample of cells from the body for laboratory testing. Common needle biopsy procedures comprise fine-needle aspiration and core needle biopsy. Needle biopsy may be used to take tissue or fluid samples from muscles, bones, and other organs, such as the liver or lungs. The sample from needle biopsy may assist the doctor to determine what’s causing a mass or lump, an infection, and inflammation. One may undergo imaging tests, such as the computerized tomography (CT) scan or an ultrasound, before needle biopsy. Sometimes these tests are used during the needle biopsy procedure to more accurately locate the area to be biopsied.

Request Sample Pages of this Research Report:

Aspiration & Biopsy Implants Market: Key Drivers

Rising prevalence of cancer

Worldwide, there has been a significant rise in the number of people suffering from cancer. This can be indorsed to a number of factors, like lifestyle changes, unhealthy diets, and growing tobacco consumption. According to estimates from the International Agency for Research on Cancer (IARC), in 2018, there were 17.0 million new cancer cases and 9.5 million cancer deaths across the globe. By 2040, the global burden is anticipated to grow to 27.5 million new cancer cases and 16.3 million cancer deaths, majorly due to the growth and aging of the population.

The incidence of cancer is the highest in more-developed regions, but mortality is relatively higher in less-developed countries owing to a lack of access to treatment facilities coupled with the lack of awareness regarding the benefits of early detection. According to the American Cancer Society, about 9.6 million people die from cancer every year, and 70% of cancer deaths occur in low-to-middle income countries like China and India; these proportions are expected to grow further by 2025. With the increasing prevalence of cancer in major regions across the globe, the demand for effective cancer diagnosis is anticipated to increase in the upcoming years. This, in turn, is expected to support the growth of the aspiration and biopsy needles market during the forecast period.

Emerging economies

Emerging economies (such as India, China, Brazil, and Mexico) are anticipated to offer significant growth opportunities for players operating in the aspiration and biopsy needles market. This can be attributed to improvements in the standard of living, the presence of a huge target population base (as a result of the rising prevalence of cancer), improvements and developments in the healthcare infrastructure, rising healthcare expenditure, and the transformation of healthcare research facilities in these countries. Adding to that, the rapid economic development coupled with rising healthcare expenditure in these emerging countries have improved access to quality healthcare, including quality cancer care.

Report Findings

The biopsy needle segment is likely to dominate the market during the forecast period

The key factors such as the rising prevalence of cancer coupled with an increasing preference for minimally invasive diagnostic procedures (over excision biopsies) are boosting the growth of the biopsy needles segment in the global aspiration & biopsy needles market.

The tumor/cancer segment is likely to dominate the market during the forecast period

The higher market share is primarily attributed to the growing prevalence of breast cancer combined with rising awareness about the disease, and increasing research activity pertaining to breast screening and diagnosis is boosting the market share of the segment.

The image-guided procedure accounted for the largest share of the market during the forecast period

The key factors propelling the market growth are the rising preference for minimally invasive biopsy and aspiration procedures.

The hospitals & surgical centers segment is likely to dominate the market during the forecast period

The key factors such as the rising prevalence of cancer coupled with cancer awareness initiatives undertaken by government and global health organizations are boosting the growth of the market.

Have a question for our analyst:

Competitive Landscape

The key players in the global aspiration & biopsy needles market are CONMED Corporation, Medtronic Plc, Olympus Corporation, Becton, Dickinson and Company, Boston Scientific Corporation, Cook Group Incorporated, Argon Medical Devices, Inc, INRAD Inc., Somatex Medical Technologies, Stryker Corporation, Cardinal Health, Remington Medical, Ranfac Corporation, HAKKO CO., LTD, and Merit Medical Systems among others.

Aspiration & Biopsy Needles Market: Segments Covered

By Product Type

  • Biopsy Needles
    • CNB Needles
    • VAB Needles
  • Aspiration Needles

By Application

  • Tumor/ Cancer Application
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Kidney Cancer
    • Bone & Bone Marrow Cancer
    • Other Cancer
  • Wound Application
  • Other Application

By Procedure

  • Image-guided Procedures
  • Ultrasound-guided Procedures
  • Stereotactic Procedures
  • CT-guided Procedures
  • MRI-guided Procedures
  • Other Image-guided Procedures
  • Nonimage-guided Procedures

By End User

  • Hospitals & Surgical Centers
  • Diagnostic Clinics & Pathology Laboratories
  • Ambulatory Care Centers
  • Research & Academic Institutes

By Region

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Aspiration & Biopsy Needles Market: Recent Developments
  • December 2021: Olympus launched the FDA 510(k)- cleared BF-UC190F endobronchial ultrasound (EBUS) bronchoscope.
  • January 2021: Hologic Inc. acquired Somatex Medical Technologies, Hologic’s strategy to provide a comprehensive suite of innovative solutions across the continuum of breast health care.
  • May 2019: Argon Medical acquired Mana tech Ltd., its exclusive distributor for the UK and Ireland.